The Myeloma Beacon The study included 13 patients with a median age of 59 years who had received a median of six prior lines of therapy. They were treated with one of three different doses of TH-302 plus dexamethasone. Of the 12 patients evaluated for response, 17 ... and more »
StreetInsider.com (subscription) Antonio Palumbo, Chief of the Myeloma Unit, Department of Oncology, at the University of Torino, a total of 402 patients received four 28-day courses of lenalidomide and low-dose dexamethasone at diagnosis, and then were randomly assigned to receive ...
Monthly Prescribing Reference A total of 1,455 chemotherapy-naïve patients undergoing anthracycline-based chemotherapy were randomly assigned to receive dexamethasone plus either NEPA or PALO. NEPA or PALO were taken orally one hour before chemotherapy and ...
MarketWatch Updated results from a Phase 1/2 study of TH-302 plus dexamethasone in patients with relapsed/refractory multiple myeloma were presented supplementing the data published in the meeting abstract (Abstract #8602). Of 12 evaluable patients, 2 achieved ...
